Skip to main content
Journal cover image

Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.

Publication ,  Journal Article
Schmittling, RJ; Archer, GE; Mitchell, DA; Heimberger, A; Pegram, C; Herndon, JE; Friedman, HS; Bigner, DD; Sampson, JH
Published in: J Immunol Methods
November 30, 2008

The epidermal growth factor receptor variant III (EGFRvIII) is a consistent tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms. As such it represents a truly tumor-specific target for antitumor immunotherapy. Although endogenous humoral responses to EGFRvIII have been reported in patients with EGFRvIII-expressing breast cancer, it is not known whether de novo responses can be generated or endogenous responses enhanced with an EGFRvIII-specific vaccine. To assess this in clinical trials, we have developed and validated an immunoassay to measure and isolate anti-EGFRvIII and anti-KLH antibodies from the serum of patients vaccinated with an EGFRvIII-specific peptide (PEPvIII) conjugated to keyhole limpet hemocyanin (KLH). Using magnetic beads with immobilized antigen we captured and detected anti-EGFRvIII and anti-KLH antibodies in serum from patients before and after vaccinations. Using this assay, we found that significant levels of antibody for tumor-specific antigen EGFRvIII (>4 microg/mL) and KLH could be induced after vaccination with PEPvIII-KLH.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Immunol Methods

DOI

ISSN

0022-1759

Publication Date

November 30, 2008

Volume

339

Issue

1

Start / End Page

74 / 81

Location

Netherlands

Related Subject Headings

  • Vaccination
  • Receptor, Fibroblast Growth Factor, Type 3
  • Male
  • Immunology
  • Humans
  • Hemocyanins
  • Glioblastoma
  • Female
  • Cancer Vaccines
  • Antibody Formation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Schmittling, R. J., Archer, G. E., Mitchell, D. A., Heimberger, A., Pegram, C., Herndon, J. E., … Sampson, J. H. (2008). Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods, 339(1), 74–81. https://doi.org/10.1016/j.jim.2008.08.004
Schmittling, Robert J., Gary E. Archer, Duane A. Mitchell, Amy Heimberger, Charles Pegram, James E. Herndon, Henry S. Friedman, Darell D. Bigner, and John H. Sampson. “Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.J Immunol Methods 339, no. 1 (November 30, 2008): 74–81. https://doi.org/10.1016/j.jim.2008.08.004.
Schmittling RJ, Archer GE, Mitchell DA, Heimberger A, Pegram C, Herndon JE, et al. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods. 2008 Nov 30;339(1):74–81.
Schmittling, Robert J., et al. “Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.J Immunol Methods, vol. 339, no. 1, Nov. 2008, pp. 74–81. Pubmed, doi:10.1016/j.jim.2008.08.004.
Schmittling RJ, Archer GE, Mitchell DA, Heimberger A, Pegram C, Herndon JE, Friedman HS, Bigner DD, Sampson JH. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods. 2008 Nov 30;339(1):74–81.
Journal cover image

Published In

J Immunol Methods

DOI

ISSN

0022-1759

Publication Date

November 30, 2008

Volume

339

Issue

1

Start / End Page

74 / 81

Location

Netherlands

Related Subject Headings

  • Vaccination
  • Receptor, Fibroblast Growth Factor, Type 3
  • Male
  • Immunology
  • Humans
  • Hemocyanins
  • Glioblastoma
  • Female
  • Cancer Vaccines
  • Antibody Formation